Hidradenitis Suppurativa Trial

Hidradenitis Suppurativa Trial

Phase III Clinical Trial – Novartis

A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa

To participate in your local study, please contact  (949) 707-5734 or fill out the form below.


Share this post

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Call us, write us, or knock on our door.

Lorem ipsum dolor sit amet, consectetur adiop iscing elit, sed do eiusmod tempor inci didunt ult labore et dolore magna aliqua.